Salut les boursomaniaques ...
... et plus particulièrement ceux qui se sont engagés dans cette biotech qui leur donne des frissons ! 
Les premiers chiffres dévoilés ce matin (se lèvent tôt, ces gens : publication à 6h58) sont positifs, l'entreprise est dans le vert pour la 1ère fois depuis 2011. Revenus en hausse, trésorerie en hausse, CA en hausse. Certes petitement mais les perspectives sont favorables.
Voilà l'explication de la bonne humeur du cours de l'action depuis l'ouverture du marché batave.
Un petit extrait :
*FINANCIAL HIGHLIGHTS*
# Revenues and other income decreased to €7.0 million (2012: €10.9 million) mainly
as a result from lower license fees as 2012 included receipt of a €7.9 million
milestone from our US partner Santarus for successful completion of study 1310
while 2013 included a €3.8 milestone from Santarus for acceptance for review of
the BLA for Ruconest by the US FDA. Sales in 2013 increased to €0.9 million
(2012: €0.8 million).
# Operating costs decreased to €12.8 million (2012: €24.1 million) as a result of
the combined effect of reduced costs for clinical studies , cost reductions
following the reorganization that was completed in the first half of 2013,
reduced inventory impairments and implementation of stringent cost control measures.
# Total net loss decreased to €14.8 million (2012: €24.1 million) as result of a
reduction in the loss from operating activities to €6.9 million from €17.5
million in 2012. Financial income and expenses resulted in a loss of €7.9
million (2012: €6.6 million) mainly as a result of non-cash charges associated
with the issue of convertible bonds and warrants and changes in the fair values
of the warrants due to re-pricing of the warrants and fluctuations in the
Pharming stock price.
# Net cash outflows from operations decreased to €8.3 million (2012: €10.3
million) while net cash inflows from financing activities amounted to €21.1
million (including €16.0 million in relation to the issue of convertible bonds
and €12.2 million issue of equity and exercises of warrants). Net cash inflows
from investing activities amounted to €0.2 million.
# Cash at the end of 2013 increased to €19.2 million (2012: €6.3 million).
# The equity position amounted to €5.0 million positive at year-end 2013, the
first time the Company reports a positive equity since the end of 2011. At
year-end 2012, the negative equity position amounted to €7.7 million.
# To date, during the first months of 2014, the exercise of warrants has provided
an additional inflow of cash of €4.2 million
Cordialement,
Docanski
